- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | FDA grants breakthrough device status to SeaStar for sepsis therapy | 2 | Investing.com | ||
| Mi | FDA erteilt Sepsis-Therapie von SeaStar den Status "Breakthrough Device" | 3 | Investing.com Deutsch | ||
| Mi | FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition | 114 | GlobeNewswire (Europe) | Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER... ► Artikel lesen | |
| SEASTAR MEDICAL Aktie jetzt für 0€ handeln | |||||
| Mo | SeaStar Medical Holding Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 02.10. | SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026 | 1 | GlobeNewswire (USA) | ||
| 01.10. | New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical's SCD Therapy for Acute Kidney Injury (AKI) | 1 | GlobeNewswire (USA) | ||
| 29.09. | SeaStar Medical CMO to present at pediatric therapy conference | 1 | Investing.com | ||
| 24.09. | SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy | 2 | GlobeNewswire (USA) | ||
| 12.09. | SeaStar Medical bei H.C. Wainwright: Studie bei Erwachsenen überschattet Small-Cap-Potenzial | 3 | Investing.com Deutsch | ||
| 13.08. | Seastar medical targets NEUTRALIZE-AKI enrollment completion around year-end or Q1 2027 as QUELIMMUNE adoption reaches 20 hospitals | 5 | Seeking Alpha | ||
| 12.08. | SeaStar Medical Holding GAAP EPS of -$0.91 beats by $0.06, revenue of $0.06M misses by $0.43M | 2 | Seeking Alpha | ||
| 12.08. | SeaStar Medical Holding Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates | 198 | GlobeNewswire (Europe) | Added 3 top-rated children's hospitals to QUELIMMUNE- pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025 Advanced enrollment in the NEUTRALIZE-AKI... ► Artikel lesen | |
| 12.08. | SeaStar Medical Holding Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08. | SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026 | 1 | GlobeNewswire (USA) | ||
| 21.07. | SeaStar Medical Holding Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 14.07. | SeaStar Medical sponsors pediatric kidney injury summit | 1 | Investing.com | ||
| 14.07. | SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI) | 2 | GlobeNewswire (USA) | ||
| 01.07. | SeaStar Medical Holding Corp - 8-K, Current Report | 3 | SEC Filings | ||
| 23.06. | SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury | 5 | GlobeNewswire (USA) |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 41,590 | -3,92 % | EQS-News: Fresenius SE & Co. KGaA: Fresenius erwirbt verbleibende 45 % an mAbxience für bis zu 750 Mio. € und erhält vollständige Kontrolle über seine Biosimilars-Plattform | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Strategische Unternehmensentscheidung
Fresenius erwirbt verbleibende 45 % an mAbxience für bis zu 750 Mio. € und erhält vollständige... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 36,720 | -1,87 % | EQS-Adhoc: Fresenius Medical Care AG: Wechsel im Vorstandsvorsitz - Shervin J. Korangy folgt auf Helen Giza | EQS-Ad-hoc: Fresenius Medical Care AG / Schlagwort(e): Personalentscheidungen / Vorstand
Fresenius Medical Care AG: Wechsel im Vorstandsvorsitz - Shervin J. Korangy folgt auf Helen... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 38,260 | -0,78 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| GERRESHEIMER | 28,420 | -2,00 % | EQS-News: Gerresheimer AG: Gerresheimer schließt Verkauf von Centor erfolgreich ab | EQS-News: Gerresheimer AG
/ Schlagwort(e): Fusionen & Übernahmen/Verkauf
Gerresheimer schließt Verkauf von Centor erfolgreich ab
01.10.2026 / 10:04 CET/CEST
Für den... ► Artikel lesen | |
| THERMO FISHER | 580,00 | -1,89 % | Thermo Fisher Scientific: Strategische Neuausrichtung und Margenwachstum! | ||
| TELADOC HEALTH | 4,901 | -1,23 % | Teladoc Health Adds Contactless Vitals and Ambient AI Scribe to Virtual Visit Platform | ||
| STRATEC | 22,000 | -3,51 % | EQS-PVR: STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: STRATEC SE
STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| HIMS & HERS HEALTH | 25,060 | -5,15 % | Hims & Hers Names Chief Medical Officers in the UK and Australia, Deepening its Investment in Local Clinical Leadership | Kultar Garcha, MD, joins as Chief Medical Officer of the UK and EMEA, and Matt Vickers, FRACGP, MBBS, BMedSci, AICGG, is named Chief Medical Officer of Hims Australia, guiding clinical strategy... ► Artikel lesen | |
| BICO GROUP | 1,966 | +1,13 % | BICO Group AB: BICO Completes Integration of Cellenion into SCIENION, Strengthening Precision Biotech Platform | BICO Group AB (publ) today announces the completion of the integration of Cellenion into SCIENION, bringing the businesses, technologies, and teams together under a single organization and brand.
This... ► Artikel lesen | |
| M1 AESTHETICS | 13,200 | +1,54 % | Dividendenbekanntmachungen (08.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A2 MILK COMPANY LIMITED NZATME0002S8 0,4135 NZD 0,2059 EUR AGRANA BETEILIGUNGS-AG AT000AGRANA3 - 0,35 EUR BANK OF CHONGQING CO LTD CNE100001QN2 0... ► Artikel lesen | |
| EUROFINS SCIENTIFIC | 75,38 | -1,57 % | Eurofins Scientific SE: Eurofins Scientific: Director/PDMR Shareholding | Eurofins Scientific SE (Paris:ERF) (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,073 | -1,88 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| FAMICORD | 2,970 | -1,33 % | EQS-News: FamiCord AG gewinnt vielversprechenden CDMO-Neukunden mit Herstellungsvereinbarung für zulassungsrelevante Phase-II/III-Studie bei anfänglichem Volumen im niedrigen einstelligen Millionen-Euro-Bereich | EQS-News: FamiCord AG
/ Schlagwort(e): Vertrag
FamiCord AG gewinnt vielversprechenden CDMO-Neukunden mit Herstellungsvereinbarung für zulassungsrelevante Phase-II/III-Studie bei... ► Artikel lesen | |
| BOSTON SCIENTIFIC | 37,445 | +0,83 % | Boston Scientific Names Fitzgerald Executive Vice President & COO In New Operating Restructure | WASHINGTON (dpa-AFX) - Boston Scientific Corp. (BSX), a medical technology company, on Wednesday announced that it has appointed Joseph M. Fitzgerald as Executive Vice President and Chief Operating... ► Artikel lesen | |
| DEXCOM | 75,00 | -0,53 % | Medtech-Branche: Citi bestätigt Abbott und Dexcom als Top-Picks |
Das Unternehmen SEASTAR MEDICAL HOLDING CORPORATION kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 3,490 Euro und damit -6,18 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SEASTAR MEDICAL HOLDING CORPORATION finden Sie auf Wallstreet Online.